Status:

UNKNOWN

Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

Lead Sponsor:

VA Greater Los Angeles Healthcare System

Conditions:

Prostate Cancer

Eligibility:

MALE

Phase:

PHASE2

Brief Summary

This is a trial of 5 fraction SBRT combined with androgen deprivation therapy for patients with localized high-risk or unfavorable intermediate risk prostate cancer

Eligibility Criteria

Inclusion

  • Histologically confirmed primary non-metastatic adenocarcinoma of the prostate
  • High-risk or unfavorable intermediate-risk as defined below:
  • High-risk localized prostate cancer, as defined by any one of the following factors:
  • Pre-biopsy or any PSA ≥20 prior to enrollment, or Gleason score 8 or higher on any biopsy core, or cT3a or higher.
  • Unfavorable intermediate risk localized prostate cancer, as defined as any of the following factors:
  • Gleason score of 4+3 or higher on any biopsy core, or Gleason score 3+4 and \>50% biopsy cores positive, or The presence of any two of the following: PSA\>10, cT2b-c, Gleason score 3+4 in any core
  • No pelvic nodal metastases (based on CT or MRI findings)
  • No distant metastases, based upon:
  • CT scan or MRI of the pelvis within 120 days prior to registration, Bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis
  • Age ≥ 18
  • KPS ≥ 70 (or ECOG 0-2)
  • Ability to understand, and willingness to sign, the written informed consent

Exclusion

  • Patients with low-risk or favorable intermediate-risk prostate cancer do not meet inclusion criteria (these patients would be eligible for SBRT off-trial as a standard of care option)
  • Patients with any evidence of distant metastases
  • Hormonal therapy (LHRH agonist or oral anti-androgen) exceeding 7 months prior to registration
  • Prior cryosurgery, HIFU or brachytherapy of the prostate
  • Prior pelvic radiotherapy
  • History of Crohn's Disease or Ulcerative Colitis

Key Trial Info

Start Date :

December 1 2016

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2025

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT04489745

Start Date

December 1 2016

End Date

January 1 2025

Last Update

July 28 2020

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.